miRNA在炎症性肠病肠道纤维化中的研究进展  

Research progress on miRNA in inflammatory bowel disease-associated intestinal fibrosis

作　　者：吴琼 张哲 刘霞[1] 张目涵 王斌斌 冯百岁[1] WU Qiong;ZHANG Zhe;LIU Xia;ZHANG Muhan;WANG Binbin;FENG Baisui(Department of Gastroenterology,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450014,China)

机构地区：[1]郑州大学第二附属医院消化内科,河南郑州450014

出　　处：《胃肠病学和肝病学杂志》2024年第12期1693-1697,共5页Chinese Journal of Gastroenterology and Hepatology

基　　金：河南省重点研发与推广专项(212102310803,222102310460);河南省医学科技攻关计划联合共建项目(LHGJ20210409)。

摘　　要：炎症性肠病(inflammatory bowel disease,IBD)主要包括克罗恩病(Crohn’s disease,CD)和溃疡性结肠炎(ulcerative colitis,UC),是一种能够引起肠道炎症的慢性复发性疾病。肠道纤维化是IBD的一种常见且严重的并发症,它难以在早期诊断,纤维化程度也难以精确评估。此外,由于目前缺乏有效的抗纤维化药物,患者往往因肠道纤维化引起的肠梗阻而需要接受肠切除手术。miRNA作为一种非编码短链RNA,在肠道纤维化的发生和发展中发挥着关键调控作用。本文就miRNA在IBD肠道纤维化的研究进展作一综述,旨在深入探讨miRNA调控IBD肠道纤维化的机制,总结miRNA在肠道纤维化诊断和治疗的研究动向,为miRNA在肠道纤维化的研究及应用领域提供理论基础。Inflammatory bowel disease(IBD),which includes Crohn′s disease(CD)and ulcerative colitis(UC),represents a group of chronic,recurrent diseases that induce inflammation in the intestinal tract.Intestinal fibrosis is a common and severe complication of IBD,and its early diagnosis is challenging,while assessing the degree of fibrosis accurately poses difficulties.Furthermore,effective anti-fibrotic medications are currently lacking,often necessitating intestinal resection surgeries for patients experiencing intestinal obstruction due to fibrosis.MiRNA,a type of non-coding short-chain RNA,play a crucial regulatory role in the development of intestinal fibrosis.This article provided a comprehensive review of the research progress on miRNA in IBD-related intestinal fibrosis,aiming to elucidate the mechanisms through which miRNA regulates IBD-associated intestinal fibrosis.It also summarized advancements in the diagnosis and treatment of intestinal fibrosis using miRNA,thereby laying a theoretical foundation for the study and application of miRNA in the field of intestinal fibrosis.

关 键 词：微小RNA 炎症性肠病 肠道纤维化 上皮-间充质转化 

分 类 号：R574.62[医药卫生—消化系统]